Akouos is a genetic medicines company dedicated to developing gene therapies with the potential to restore, improve or preserve hearing.
Akouos is building the leading gene therapy company focused on hearing disorders.
Akouos was founded in 2016 by Manny Simons, Michael Mckenna, William Sewell, Richard Smith and Luk Vandenberghe. The company is headquartered in Boston, Massachusetts.
Akouos is focused on developing precision therapies for forms of sensorineural hearing loss by leveraging its adeno-associated viral (AAV) vector-based gene therapy platform.
Akouos' first gene therapy development program, AK-OTOF, is for individuals with sensorineural hearing loss due to mutations in the otoferlin (OTOF) gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc.
Akouos is backed by New Enterprise Associates, Pivotal bioVenture Partners, Cormorant Asset Management, Cowen Healthcare Investments, EcoR1 Capital and others. The company raised $105M in a Series B round on Mar 03, 2020. This brings Akouos' total funding to $162.5M to date.